The growing biopharma
industry in China has resulted in the creation of lucrative business
opportunities for contract service providers; region-specific advantages have
also attracted several foreign sponsors entities over the last few years
Roots Analysis is pleased to
announce the publication of its recent study, titled, “China
Biopharmaceutical Contract Manufacturing Market, 2020-2030.”
The report features an extensive study of the
current market landscape and future opportunities associated with the contract
manufacturing of biopharmaceuticals in China. The study also features a
detailed analysis of key drivers and trends related to this evolving domain. In
addition to other elements, the study includes:
§
A detailed assessment
of the current market landscape of companies offering contract manufacturing services
for biopharmaceuticals in China.
§
An analysis of the
partnerships that have been established in this domain, in the recent past.
§
An analysis of the
expansion initiatives undertaken by contract manufacturers in China, in order
to augment their capabilities, in the recent past.
§
A detailed analysis
of more than 1500 clinical trials related to biopharmaceuticals that have been
/ are being / are likely to be conducted in China.
§
An estimate of the
overall, installed capacity for manufacturing biopharmaceuticals, based on data
reported by industry stakeholders in the public domain.
§
An analysis of the initiatives
of big biopharma players engaged in this domain.
§
A qualitative
analysis, highlighting the various factors that need to be taken into
consideration by drug / therapy developers while deciding whether to
manufacture their respective products in-house or engage the services of a CMO.
§
Detailed profiles of key
players that have a diverse range of capabilities for the development, manufacturing,
and packaging of biopharmaceutical products.
§
A case study
comparing the key characteristics of large molecule and small molecule drugs.
§
A discussion on
industry affiliated trends, key drivers, and challenges, under a SWOT
framework, which are likely to impact the evolution of this field.
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
§
API
§
FDF
- Type
of Expression System Used
§
Mammalian
§
Microbial
§
Others
§
Preclinical /
Clinical
§
Commercial
§
Small
§
Mid-sized
§
Large / Very Large
§
Antibody
§
Vaccine
§
Others
Key
companies covered in the report
§
ChemPartner Biologics
§
JHL Biotech
§
JOINN Biologics
§
MabPlex
§
Mycenax Biotech
§
WuXi AppTec
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html
Other Recent
Offerings
1. China Pharmaceutical
Contract Manufacturing Services Market, 2020-2030
2.
Live Biotherapeutics
Products and Microbiome Contract Manufacturing Market: Focus on Active
Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
3.
Oligonucleotide
Synthesis, Modification and Purification Services Market: Focus on Research,
Diagnostic and Therapeutic Applications, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com